Antibodies directed against amyloid-beta peptide and methods using same
AssigneeRinat Neuroscience Corp.
InventorsArnon Rosenthal, Jaume Pons, Wei-Hsien Ho, Jan Markus Grimm
Life of this patent
Estimating the term…
Abstract
Monoclonal antibody 9TL and antibodies derived from 9TL directed against amyloid-beta peptide and methods of using same for diagnosing and treatment of Alzheimer's disease and Aβ peptide associated diseases are described. Methods of using antibodies directed against amyloid-beta peptide having impaired effector function for treatment of Alzheimer's disease and Aβ peptide associated diseases are also described.
Claims18
A method for treating a disease characterized by aberrant deposition of a protein in the brain of a subject, comprising administering to the subject an effective amount of an antibody comprising three complementarity determining regions (CDRs) from a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:1, and three CDRs from a light chain variable region comprising the amino acid sequence of SEQ ID NO:2, wherein the antibody specifically binds to a β-amyloid peptide, and wherein the disease is cerebral amyloid angiopathy.
A method for treating a disease associated with aberrant deposition of β-amyloid in a subject, comprising administering to the subject an effective amount of an antibody that specifically binds to a β-amyloid peptide or an aggregated form of a β-amyloid peptide, wherein the antibody comprises an Fc region with a variation from a naturally occurring Fc region, wherein the variation results in impaired effector function, and further wherein the antibody comprises a heavy chain variable region comprising:
- (a) a CDR1 comprising the amino acid sequence of SEQ ID NO:3;
- (b) a CDR2 comprising the amino acid sequence of SEQ ID NO:4;
- and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO:5;
- and a light chain variable region comprising:
- (d) a CDR1 comprising the amino acid sequence of SEQ ID NO:6;
- (e) a CDR2 comprising the amino acid sequence of SEQ ID NO:7;
- and (f) a CDR3 comprising the amino acid sequence of SEQ ID NO:8;
- wherein the disease is cerebral amyloid angiopathy.
Dependencies are inferred from the claim text.